newsfilter
← Latest News
Business Wire·

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance